Literature DB >> 24418286

Contrast-enhanced CT and diffusion-weighted MR imaging: performance as a prognostic factor in patients with pancreatic ductal adenocarcinoma.

Yoshihiko Fukukura1, Koji Takumi2, Michiyo Higashi3, Hiroyuki Shinchi4, Kiyohisa Kamimura2, Tomohide Yoneyama2, Akihiro Tateyama2.   

Abstract

OBJECTIVE: To determine whether contrast enhancement of CT and apparent diffusion coefficient on diffusion-weighted MR imaging are important parameters that can predict outcomes for patients with pancreatic ductal adenocarcinoma.
MATERIALS AND METHODS: Ninety-two patients with histologically confirmed pancreatic ductal adenocarcinoma who underwent quadriphasic CT (including unenhanced, pancreatic parenchymal, portal venous and delayed phases) and fat-suppressed single-shot echo-planar diffusion-weighted MR imaging at 3.0 T were retrospectively analyzed to investigate prognostic factors. Overall survival curves were drawn using the Kaplan-Meier method. Effects on survival of variables including age, sex, tumor location, tumor size, TNM stage, carbohydrate antigen 19-9, carcinoembryonic antigen, treatment, tumor contrast enhancement and apparent diffusion coefficient values were analyzed in univariate analysis using the log-rank test. Variables were analyzed in multivariate analyses using the Cox proportional hazards regression model.
RESULTS: Median survival for the entire patient population was 18.2 months. Higher contrast enhancement during all phases was associated with significantly longer overall survival (P<0.001 for all phases). The difference in overall survival between groups divided by median apparent diffusion coefficient value was not significant (P=0.672). TNM stage (P=0.026) and tumor contrast enhancement on CT (P=0.027) were significantly related to survival in multivariate analysis.
CONCLUSIONS: Poor enhancement of pancreatic adenocarcinomas on enhanced CT is associated with reduced patient survival.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Computed tomography; Diffusion magnetic resonance imaging; Neoplasm; Pancreas; Prognosis

Mesh:

Year:  2013        PMID: 24418286     DOI: 10.1016/j.ejrad.2013.12.016

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  15 in total

Review 1.  Diffusion-weighted imaging of pancreatic cancer.

Authors:  Riccardo De Robertis; Paolo Tinazzi Martini; Emanuele Demozzi; Flavia Dal Corso; Claudio Bassi; Paolo Pederzoli; Mirko D'Onofrio
Journal:  World J Radiol       Date:  2015-10-28

2.  Extracellular volume fraction determined by equilibrium contrast-enhanced multidetector computed tomography as a prognostic factor in unresectable pancreatic adenocarcinoma treated with chemotherapy.

Authors:  Yoshihiko Fukukura; Yuichi Kumagae; Ryutaro Higashi; Hiroto Hakamada; Koji Takumi; Kosei Maemura; Michiyo Higashi; Kiyohisa Kamimura; Masanori Nakajo; Takashi Yoshiura
Journal:  Eur Radiol       Date:  2018-06-19       Impact factor: 5.315

Review 3.  Prognostication and response assessment in liver and pancreatic tumors: The new imaging.

Authors:  Riccardo De Robertis; Paolo Tinazzi Martini; Emanuele Demozzi; Gino Puntel; Silvia Ortolani; Sara Cingarlini; Andrea Ruzzenente; Alfredo Guglielmi; Giampaolo Tortora; Claudio Bassi; Paolo Pederzoli; Mirko D'Onofrio
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

4.  A predictive model for recurrence after upfront surgery in patients with resectable pancreatic ductal adenocarcinoma (PDAC) by using preoperative clinical data and CT characteristics.

Authors:  Ningzi Tian; Dong Wu; Lei Zhu; Mengsu Zeng; Jianke Li; Xiaolin Wang
Journal:  BMC Med Imaging       Date:  2022-07-03       Impact factor: 2.795

5.  Prognostic value of preoperative enhanced computed tomography as a quantitative imaging biomarker in pancreatic cancer.

Authors:  Jian-Feng Gao; Yu Pan; Xian-Chao Lin; Feng-Chun Lu; Ding-Shen Qiu; Jun-Jun Liu; He-Guang Huang
Journal:  World J Gastroenterol       Date:  2022-06-14       Impact factor: 5.374

6.  Pre-operative radiomics model for prognostication in resectable pancreatic adenocarcinoma with external validation.

Authors:  Gerard M Healy; Emmanuel Salinas-Miranda; Rahi Jain; Xin Dong; Dominik Deniffel; Ayelet Borgida; Ali Hosni; David T Ryan; Nwabundo Njeze; Anne McGuire; Kevin C Conlon; Jonathan D Dodd; Edmund Ronan Ryan; Robert C Grant; Steven Gallinger; Masoom A Haider
Journal:  Eur Radiol       Date:  2021-11-10       Impact factor: 7.034

7.  Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.

Authors:  Amir A Borhani; Rohit Dewan; Alessandro Furlan; Natalie Seiser; Amer H Zureikat; Aatur D Singhi; Brian Boone; Nathan Bahary; Melissa E Hogg; Michael Lotze; Herbert J Zeh; Mitchell E Tublin
Journal:  AJR Am J Roentgenol       Date:  2019-12-04       Impact factor: 3.959

Review 8.  Anatomical, Physiological, and Molecular Imaging for Pancreatic Cancer: Current Clinical Use and Future Implications.

Authors:  John Chang; Donald Schomer; Tomislav Dragovich
Journal:  Biomed Res Int       Date:  2015-06-04       Impact factor: 3.411

9.  Clinically determined type of 18F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer.

Authors:  Jae Uk Chong; Ho Kyoung Hwang; Jin Ho Lee; Mijin Yun; Chang Moo Kang; Woo Jung Lee
Journal:  PLoS One       Date:  2017-02-24       Impact factor: 3.240

10.  CT Imaging Biomarkers Predict Clinical Outcomes After Pancreatic Cancer Surgery.

Authors:  Liang Zhu; Xiaohua Shi; Huadan Xue; Huanwen Wu; Ge Chen; Hao Sun; Yonglan He; Zhengyu Jin; Zhiyong Liang; Zhuoli Zhang
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.